Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Poseida Therapeutics, Inc. (PSTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/14/2023 SC 13D Astellas US LLC reports a 8.7% stake in POSEIDA THERAPEUTICS, INC.
08/11/2023 D Form D - Notice of Exempt Offering of Securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Investor Contact:"
08/07/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "Securities Purchase Agreement, by and between the Company and Astellas",
"Registration Rights Agreement, by and between the Company and Astellas",
"CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.",
"Investor Contact:",
"Investor Contact:"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/01/2023 8-K Termination of a Material Definitive Agreement, Other Events  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
02/22/2023 8-K Quarterly results
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in POSEIDA THERAPEUTICS INC
01/31/2023 8-K Quarterly results
01/17/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
01/12/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
12/06/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
09/07/2022 8-K Other Events  Interactive Data
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
08/04/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/03/2022 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/03/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/03/2022 8-K Investor presentation
Docs: "Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies",
"Presentation of Poseida Therapeutics, Inc."
06/16/2022 8-K Quarterly results
05/25/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy